Obstructive Hypertrophic Cardiomyopathy Hcm — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for obstructive hypertrophic cardiomyopathy hcm . 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
8
Active US patents
44/100
Avg vulnerability
$600M
Annual revenue covered

Originators in Obstructive Hypertrophic Cardiomyopathy Hcm

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating obstructive hypertrophic cardiomyopathy hcm . Each bar = one year. Y-axis scaled to peak year (4 patents).

4
34
4
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Camzyos
MAVACAMTEN
 Bristol-Myers Squibb 8 44 $600M 2034-06-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19

Related